# reload+after+2024-01-23 14:47:02.482063
address1§7210 Frederick-Banting
address2§Suite 100
city§St-Laurent
state§QC
zip§H4S 2A1
country§Canada
phone§857 412 7018
website§https://www.reparerx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
fullTimeEmployees§180
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Lloyd Mitchell Segal', 'age': 59, 'title': 'President, CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 913395, 'exercisedValue': 0, 'unexercisedValue': 11191360}, {'maxAge': 1, 'name': 'Dr. Michael  Zinda Ph.D.', 'age': 52, 'title': 'Executive VP & Chief Scientific Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 641532, 'exercisedValue': 0, 'unexercisedValue': 1476505}, {'maxAge': 1, 'name': 'Dr. Maria  Koehler M.D., Ph.D.', 'age': 66, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 682803, 'exercisedValue': 0, 'unexercisedValue': 1278955}, {'maxAge': 1, 'name': 'Dr. Daniel  Durocher Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Frank  Sicheri Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Agnel  Sfeir Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steve  Forte', 'age': 44, 'title': 'Executive VP & CFO', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 608524, 'exercisedValue': 0, 'unexercisedValue': 3406980}, {'maxAge': 1, 'name': 'Mr. Daniel  Belanger', 'title': 'Executive Vice President of Human Resource', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Cameron  Black', 'title': 'Executive Vice President of Discovery', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kim A. Seth Ph.D.', 'title': 'Executive VP & Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.597
priceToSalesTrailing12Months§5.03754
currency§USD
dateShortInterest§1702598400
forwardEps§-3.29
exchange§NMS
quoteType§EQUITY
shortName§Repare Therapeutics Inc.
longName§Repare Therapeutics Inc.
firstTradeDateEpochUtc§1592573400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f56fdf17-21e6-3de0-b509-707b7aee6c59
gmtOffSetMilliseconds§-18000000
targetHighPrice§29.0
targetLowPrice§8.0
targetMeanPrice§21.17
targetMedianPrice§25.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§5.504
grossMargins§-1.11886
ebitdaMargins§-1.8315899
trailingPegRatio§None
